Noxopharm Ltd. engages in the research and development of drugs. It focuses on sensitizing cancer cells to radiotherapy and chemotherapy. The company was founded by Graham Kelly on October 27, 2015 and is headquartered in Chatswood, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company